Abstract
Background: The risk factors for Systemic Autoimmune Disease (SAD)s with antiarrhythmic drugs (AAD)s in arrhythmia patients are still unclear.
Aims: This study discussed these risk factors for SADs with AADs in arrhythmia patients.
Methods: This study was a retrospective cohort design and analyzed this relationship in an Asian population. Patients without a prior diagnosis of SADs were identified from Taiwan's National Health Insurance Research Database from January 1st , 2000, to December 31st , 2013. Cox regression models estimated the hazard ratio (HR) with a 95% confidence interval (CI) of SAD.
Results: We estimated the data of participants aged ≧ 20 or ≦ 100 years old and free of SADs at baseline. AAD users (n = 138376) had a significantly increased risk of SADs over non-AAD users. There was a significantly higher risk of developing SADs in all age and sex categories. The patients who received AADs, the autoimmune disease with the significantly higher risk was Systemic Lupus Erythematous (SLE) (adjusted HR (aHR) 1.53, 95% CI, 1.04-2.26), Sjögren syndrome (SjS) (For adjusted HR (For aHR) For 2.06 For, 95% CI, 1.59-2.66) and Rheumatoid Arthritis (RA) (aHR, 1.57, 95% CI, 1.26-1.94).
Conclusion: We concluded that there were statistical associations between AADs and SADs, and the higher incidence was SLE, SjS and RA in arrhythmia patients.
Keywords: Systemic autoimmune disease, antiarrhythmic drug, medication risk assessment, the asian population, Arrhythmia Patients, AAD.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Risk of Systemic Autoimmune Diseases with Antiarrhythmic Drugs in Arrhythmia Patients: A Retrospective Cohort Study
Volume: 23 Issue: 14
Author(s): Jiun-Jie Lin, Hung-Yi Chen*, Mei-Chen Lin and Chung-Y. Hsu
Affiliation:
- Institute of Pharmacy, China Medical University, Taichung, Taiwan
- Department of Pharmacy, China Medical University Hospital, Beikang Campus, Yunlin, Taiwan
Keywords: Systemic autoimmune disease, antiarrhythmic drug, medication risk assessment, the asian population, Arrhythmia Patients, AAD.
Abstract:
Background: The risk factors for Systemic Autoimmune Disease (SAD)s with antiarrhythmic drugs (AAD)s in arrhythmia patients are still unclear.
Aims: This study discussed these risk factors for SADs with AADs in arrhythmia patients.
Methods: This study was a retrospective cohort design and analyzed this relationship in an Asian population. Patients without a prior diagnosis of SADs were identified from Taiwan's National Health Insurance Research Database from January 1st , 2000, to December 31st , 2013. Cox regression models estimated the hazard ratio (HR) with a 95% confidence interval (CI) of SAD.
Results: We estimated the data of participants aged ≧ 20 or ≦ 100 years old and free of SADs at baseline. AAD users (n = 138376) had a significantly increased risk of SADs over non-AAD users. There was a significantly higher risk of developing SADs in all age and sex categories. The patients who received AADs, the autoimmune disease with the significantly higher risk was Systemic Lupus Erythematous (SLE) (adjusted HR (aHR) 1.53, 95% CI, 1.04-2.26), Sjögren syndrome (SjS) (For adjusted HR (For aHR) For 2.06 For, 95% CI, 1.59-2.66) and Rheumatoid Arthritis (RA) (aHR, 1.57, 95% CI, 1.26-1.94).
Conclusion: We concluded that there were statistical associations between AADs and SADs, and the higher incidence was SLE, SjS and RA in arrhythmia patients.
Export Options
About this article
Cite this article as:
Lin Jiun-Jie, Chen Hung-Yi*, Lin Mei-Chen and Hsu Chung-Y., Risk of Systemic Autoimmune Diseases with Antiarrhythmic Drugs in Arrhythmia Patients: A Retrospective Cohort Study, Endocrine, Metabolic & Immune Disorders - Drug Targets 2023; 23 (14) . https://dx.doi.org/10.2174/1871530323666230419085348
DOI https://dx.doi.org/10.2174/1871530323666230419085348 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ranolazine and its Antiarrhythmic Actions
Cardiovascular & Hematological Agents in Medicinal Chemistry Pathogenesis of Neointima Formation Following Vascular Injury
Cardiovascular & Hematological Disorders-Drug Targets Exciting News from the Messenger
Current Neurovascular Research An “Enigmatic” L-Carnosine (β-Alanyl-L-Histidine)? Cell Proliferative Activity as a Fundamental Property of a Natural Dipeptide Inherent to Traditional Antioxidant, Anti-Aging Biological Activities: Balancing and a Hormonally Correct Agent, Novel Patented Oral Therapy Dosage Formulation for Mobility, Skeletal Muscle Power and Functional Performance, Hypothalamic-Pituitary- Brain Relationship in Health, Aging and Stress Studies
Recent Patents on Drug Delivery & Formulation Extraction of Quantitative Anatomical Information from Coronary Angiographies
Current Bioinformatics Effects of Long-term Use of Proton Pump Inhibitors on Systemic Arterial Stiffness and Pulse Wave Velocity
Current Vascular Pharmacology Novel High Throughput Polymer Biocompatibility Screening Designed for SAR (Structure-Activity Relationship): Application for Evaluating Polymer Coatings for Cardiovascular Drug-Eluting Stents
Combinatorial Chemistry & High Throughput Screening Left Ventricular Noncompaction: New Insights into a Poorly Understood Disease
Current Cardiology Reviews Graphical Abstracts
Protein & Peptide Letters The Gut Microbiota and Lipid Metabolism: Implications for Human Health and Coronary Heart Disease
Current Medicinal Chemistry Therapeutic Angiogenesis: Recent and Future Prospects of Gene Therapy in Peripheral Artery Disease
Current Gene Therapy Brutons Tyrosine Kinase as a New Therapeutic Target
Anti-Cancer Agents in Medicinal Chemistry Fruit as Potent Natural Antioxidants and Their Biological Effects
Current Pharmaceutical Biotechnology The Molecular Basis for the Post-Translational Addition of Amino Acids by L/F Transferase in the N-End Rule Pathway
Current Protein & Peptide Science Editorial [(Hot Topic Novel Drug Therapies in the Treatment of SAH) Guest Editors: Surya Karri and Christopher S. Ogilvy]
Current Drug Safety Intravitreal Dexamethasone Implant <i>versus</i> Intravitreal Ranibizumab Injection for Treatment of Non-Proliferative Diabetic Macular Edema: A Prospective, Randomized and Blinded Trial
Current Drug Delivery Protective Effects and Mechanisms of Action of Ulinastatin against Cerebral Ischemia-Reperfusion Injury
Current Pharmaceutical Design The Impact of Cardiovascular Diseases on Cardiovascular Regulation During Exercise in Humans: Studies on Metaboreflex Activation Elicited by the Post-exercise Muscle Ischemia Method
Current Cardiology Reviews The ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) Trial: A Step Forward in the Treatment of Early Breast Cancer
Reviews on Recent Clinical Trials High Prevalence of AH in HIV Patients on ART, in Bahia, Brazil
Current HIV Research